SARS-CoV-2 JN.1 variant evasion of IGHV3-53/3-66 B cell germlines.


Journal

Science immunology
ISSN: 2470-9468
Titre abrégé: Sci Immunol
Pays: United States
ID NLM: 101688624

Informations de publication

Date de publication:
09 Aug 2024
Historique:
medline: 9 8 2024
pubmed: 9 8 2024
entrez: 9 8 2024
Statut: ppublish

Résumé

The severe acute respiratory syndrome coronavirus 2 variant JN.1 recently emerged as the dominant variant despite having only one amino acid change on the spike (S) protein receptor binding domain (RBD) compared with the ancestral BA.2.86, which never represented more than 5% of global variants. To define at the molecular level the JN.1 ability to spread globally, we interrogated a panel of 899 neutralizing human monoclonal antibodies. Our data show that the single leucine-455-to-serine mutation in the JN.1 spike protein RBD unleashed the global spread of JN.1, likely occurring by elimination of more than 70% of the neutralizing antibodies mediated by IGHV3-53/3-66 germlines. However, the resilience of class 3 antibodies with low neutralization potency but strong Fc functions may explain the absence of JN.1 severe disease.

Identifiants

pubmed: 39121195
doi: 10.1126/sciimmunol.adp9279
doi:

Substances chimiques

Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Antibodies, Monoclonal 0
Immunoglobulin Heavy Chains 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eadp9279

Auteurs

Ida Paciello (I)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Giuseppe Maccari (G)

Data Science for Health (DaScH) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Giulio Pierleoni (G)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.

Federica Perrone (F)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.
Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.

Giulia Realini (G)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Marco Troisi (M)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Gabriele Anichini (G)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Maria Grazia Cusi (MG)

Virology Unit, Department of Medical Biotechnologies, University of Siena, Siena, Italy.

Rino Rappuoli (R)

Department of Biotechnology, Chemistry and Pharmacy, University of Siena, Siena, Italy.
Fondazione Biotecnopolo di Siena, Siena, Italy.

Emanuele Andreano (E)

Monoclonal Antibody Discovery (MAD) Lab, Fondazione Toscana Life Sciences, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH